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INTRODUCTION
Embryonic development and tumor growth share several 
features. For instance, homeobox genes, which are crucial 
for body plan organization, can also be involved in tumori-
genesis either as tumor suppressors or as oncogenes. In line 
with this, it is now well established that tumors represent 
cellular masses that are structurally organized but anatomi-
cally and functionally abnormal compared with healthy or-
gans (Egeblad et al., 2010). Tumor growth is driven by the 
intrinsic properties of the cells and by cell interactions with 
their environment. The role of cell interactions between 
tumor cells and other cell types, such as cancer-associated fi-
broblasts, immune cells, or endothelial cells, has been widely 
described (Lujambio et al., 2013; Marusyk et al., 2014). 
However, much less is known about whether and how epi-
thelial cells at different premalignant stages can interact and 
participate in tumor initiation.
Besides its role in embryonic development, the ho-
meobox gene Cdx2 is an important regulator of the dy-
namic homeostasis of the gut, providing tissue identity to 
the stem cells and coordinating cell proliferation and dif-
ferentiation during the constant renewal of the epithelium 
(Verzi et al., 2011; Stringer et al., 2012; Simmini et al., 2014). 
Its expression is frequently altered in human colorectal can-
cers (CRCs) and in animal models of intestinal cancers, and 
convergent studies in mice have established its tumor sup-
pressor role in the gut (Aoki et al., 2003; Bonhomme et al., 
2003; Gross et al., 2008; Hryniuk et al., 2014). Recently, a 
functional link between B-Raf activation and loss of Cdx2 
in a subset of CRCs has demonstrated the relevance of the 
combination of these molecular events within tumor cells 
and the importance of cell differentiation dictated by Cdx2 
against intestinal tumorigenesis (Sakamoto et al., 2017; Tong 
et al., 2017). In the present study, starting from data obtained 
in a collection of human CRCs, we developed an original 
mouse model with the goal of uncovering the importance 
of indirect interactions between different types of epithelial 
cells at premalignant stages in triggering tumorigenesis. The 
results highlight a novel property of Cdx2 in the gut, in that 
this homeobox gene exerts a non–cell-autonomous tumor 
suppressor activity. In addition, a new paradigm for meta-
plasia emerges, in the sense that metaplastic cells, widely 
considered as precancerous, can induce the tumorigenic 
evolution of adjacent nonmetaplastic cells without them-
selves becoming cancerous.
Developmental genes contribute to cancer, as reported for the homeobox gene Cdx2 playing a tumor suppressor role in 
the gut. In this study, we show that human colon cancers exhibiting the highest reduction in CDX2 expression belong to 
the serrated subtype with the worst evolution. In mice, mosaic knockout of Cdx2 in the adult intestinal epithelium in-
duces the formation of imperfect gastric-type metaplastic lesions. The metaplastic knockout cells do not spontaneously 
become tumorigenic. However, they induce profound modifications of the microenvironment that facilitate the tumori-
genic evolution of adjacent Cdx2-intact tumor-prone cells at the surface of the lesions through NF-κB activation, in-
duction of inducible nitric oxide synthase, and stochastic loss of function of Apc. This study presents a novel paradigm 
in that metaplastic cells, generally considered as precancerous, can induce tumorigenesis from neighboring nonmetaplas-
tic cells without themselves becoming cancerous. It unveils the novel property of non–cell-autonomous tumor suppressor 
gene for the Cdx2 gene in the gut.
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RESULTS
Human serrated-type colon cancers with a stem cell 
signature exhibit a strong reduction of CDX2
Analyzing the expression of the CDX2 homeobox gene in a 
cohort of 566 human CRCs (Cartes d’Identité des Tumeurs 
study) previously classified into six subtypes (Marisa et al., 
2013) revealed a down-regulation in two subtypes: the C2 
subtype, enriched with microsatellite instable and hyper-
mutated tumors, and a stronger down-regulation in the C4 
subtype characterized by serrated precursor neoplasia, stroma 
infiltration, and a stem cell–like/mesenchymal signature 
(Fig. 1, A and B). In the consensus classification system (Guin-
ney et al., 2015), the same down-regulation was also observed 
in subtypes CMS1 and CMS4, including the C2 and C4 sub-
types from Marisa et al. (2013) (Fig. S1). Using an unsuper-
vised approach fixing the threshold at the median value of 
CDX2 in the C4 subtype, patients of the whole cohort below 
the threshold exhibited worse disease-free survival (Fig. 1 C). 
Within the C4 subtype, disease-free survival was even worse 
in patients below the threshold compared with patients above 
the threshold (Fig. 1 D). Thus, the strong reduction of CDX2 
correlates with poor evolution of the disease.
Loss of function of Cdx2 in the mouse intestine induces 
imperfect gastric-type metaplastic lesions in the cecum, 
which do not spontaneously undergo cancerous evolution
To address the pathological relevance of the loss of expres-
sion of Cdx2, mosaic gene knockout was induced in the gut 
epithelium of adult AhCreERT::Cdx2f/f mice, as described 
previously (Stringer et al., 2012). Mosaic knockout is man-
datory for the current long-term studies because massive loss 
of function of Cdx2 is lethal as a result of digestive problems 
(Verzi et al., 2011). Within 4–6 wk after gene knockout by 
β-naphthoflavone and tamoxifen (βNF+Tam) administra-
tion, the AhCreERT::Cdx2f/f mice exhibited subsurface cysts 
throughout the small intestine that did not evolve with time, 
as previously reported (Stringer et al., 2012). In addition, after 
4 mo, all the mice analyzed in this study (n > 25) developed 
one to two polypoid lesions in the cecum, and in 20% of the 
mice, lesions were also found in the very distal ileum and 
Figure 1. CDX2 gene expression level in 566 human colon cancers and 19 nontumoral samples of the GSE39582 dataset. (A) Boxplot of the level 
of CDX2 expression in the 443 CRC samples of the discovery set organized in the six subtypes according to Marisa et al. (2013) (C1–C6). (B) Boxplot of the 
CDX2 expression level in the 123 samples of the validation set organized in six subtypes. Data are given ± SD. (C) Disease-free survival comparing CDX2high 
versus CDX2low CRC in the GSE39582 dataset. The cutoff for low versus high CDX2 expression is fixed at the median of the C4 group. CDX2low patients ex-
hibit a significantly reduced disease-free survival (P < 0.019). (D) Disease-free survival comparing CDX2high versus CDX2low CRC in the C4 subtype. CDX2low 
patients exhibit a significantly reduced disease-free survival (P = 0.009). P-values were calculated with the log-rank test.
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proximal colon (Fig. 2 A). These lesions did not compromise 
the life span of the animals (see Fig. 5 A). As shown in Fig. 2 
(A and B), the lesions consisted of Cdx2-devoid glands inter-
mingled with few Cdx2-intact glands, reflecting the mosaic 
ablation of the gene. They were covered by a single-layered 
polarized epithelium with local erosion in surface and exhib-
ited signs of inflammation, with the presence of eosinophils 
and neutrophils in the stroma. Histologically, the lesions con-
sisted of fundic-type glandular structures with dilated cysts 
together with areas of foveolar hyperplasia and antral-type 
glands covered by a polarized epithelium with nuclei reg-
ularly distributed at the cell base. They shared histological 
properties with glandular cystic and hyperplastic polyps re-
ported in the human stomach but differed from typical hy-
perplastic polyps of the intestine. By immunohistochemistry 
(Fig. 2 C), the cecal lesions showed a loss of expression of 
intestinal proteins known to be downstream targets of Cdx2, 
such as the orthologous homeoprotein Cdx1 and the mucin 
Muc2, and conversely the onset of expression of gastric pro-
teins including Claudin-18, Tff1, and Tff2. However, unlike 
the cecal foregut-type heteroplasia already developing during 
embryogenesis in heterozygous Cdx2+/− mice (Beck et al., 
1999; Stringer et al., 2008), the lesions of AhCreERT::Cdx2f/f 
mice failed to express Sox2. To further characterize them 
at the molecular level, we determined their transcriptomic 
profile and compared it with normal cecum and stomach 
and also with cecal foregut-type heteroplasia developing in 
Cdx2+/− mice. This led to identification of a large number of 
genes (5,915) altered in the lesions of AhCreERT::Cdx2f/f mice 
compared with normal cecum (Table S1, sheet 1). The large 
number of genes is consistent with the Cdx2 protein being a 
major regulator of intestinal homeostasis and with its binding 
to ∼14,000 chromatin sites across the genome of enterocytes 
(Verzi et al., 2010). Among them, transcripts for intestinal 
markers were strongly reduced (i.e., Alpi, Muc3/13, Cdh17, 
Cdhr2/5, Fabp2, Slc51a/b, Cdx1, and Isx), whereas those for 
several gastric markers were turned on (i.e., Cldn18, Ctse, 
Gkn1/2/3, Muc1/6, Ptprn2, Tff1/2, Vsig1, Gsdma2, Krt23, 
Fxyd3, and Foxq1; Fig. 2 D; and Table S1, sheet 2). Yet the le-
sions of adult AhCreERT::Cdx2f/f mice exhibited a lower and 
more heterogeneous expression of gastric genes compared 
with normal stomach and also with the foregut-type het-
eroplasia of Cdx2+/− mice; moreover, several typical markers 
even failed to turn on (Fig. 2 D). Thus, we concluded that in 
the long term, the loss of Cdx2 produces cecal lesions char-
acterized by an imperfect gastric-type metaplastic phenotype.
Because metaplastic lesions are commonly considered 
to be precancerous in many organs, we questioned the patho-
logical significance of the cecal lesions developing in Ah-
CreERT::Cdx2f/f mice. In these lesions, gene ontology terms 
related to cancer, neoplasia, cell transformation, cell prolif-
eration, cell survival, and growth of tumors were enriched, 
whereas those for apoptosis and cell death of tumor cells were 
underrepresented (Fig. 3 A). However, the pathohistological 
examination failed to display any dysplastic structure. Ki67 
immunostaining revealed an important number of prolifer-
ating cells unevenly distributed predominantly in the middle 
third of the lesions, which is reminiscent of the localization 
of proliferating cells in the isthmus of the gastric mucosa, 
unlike the crypts in the intestine (Fig. 3 B). The canonical 
Wnt pathway was not abnormally activated, as indicated by 
β-catenin remaining associated with the plasma membranes 
without cytoplasmic/nuclear translocation (Fig. 3 B). How-
ever, the formation of the lesions strongly impacted the stem 
cell compartment, as suggested by the altered expression, ei-
ther up or down, of ∼45% (173/384) of the genes of the 
intestinal stem cell signature (Muñoz et al., 2012; Table S1, 
sheet 3). For instance, the RNA sequencing data showed a 
strong stimulation of Sox9 (6×) and Olfm4 (>200×). This 
prompted us to analyze the tissue distribution of the corre-
sponding proteins (Fig. 3, B and C). The Sox9 protein, present 
at the bottom of the glands in the normal stomach and at the 
crypt base all along the gut, was strongly expressed in both 
Cdx2-depleted glands of the lesions and in the few embed-
ded Cdx2-intact glands, and also heterogeneously in the sur-
face epithelium of the lesions. The Olfm4 protein, present in 
the stem/progenitor cells of the small intestine but in neither 
the mouse stomach nor in the cecum and colon (except for 
low expression in rare glands/crypts), became strongly ex-
pressed in the Cdx2-depleted glands of the lesions, but it was 
not turned on in either the embedded Cdx2-intact glands 
or in the surface epithelium. Interestingly, although the Sox9 
pattern was similar in the lesions of AhCreERT::Cdx2f/f mice 
and in the foregut-type heteroplasia of Cdx2+/− mice, the 
Olfm4 pattern was very different because this protein was 
almost absent in the heteroplasia, with the exception of few 
clusters of glands histologically indistinguishable from the 
Olfm4-negative glands (Fig. 4 A).
The patterns obtained in the cecal lesions of 
AhCreERT::Cdx2f/f mice were compared with those observed 
in human lesions (Fig.  4 B). In human gastric hyperplastic 
polyps, the expression of Sox9 and Olfm4 was strong in more 
than half of the glandular structures. In contrast, in gastric-type 
heterotopia of the duodenum, strong Olfm4 was observed 
in only few glands (<10%). Finally, Meckel diverticula with 
gastric-type differentiation showed only rare structures ex-
pressing Sox9 at a low level, and no expression of Olfm4. 
All these human lesions failed to express Cdx2. These data 
are consistent with the notion that the imperfect gastric-type 
metaplastic lesions arising in the cecum of AhCreERT::Cdx2f/f 
mice share properties with human gastric hyperplastic polyps.
Based on the high level of cell proliferation and the 
perturbation of the stem cell compartment in the cecal le-
sions of AhCreERT::Cdx2f/f mice, a series of five animals were 
maintained alive up to 23–24 mo (20–21 mo after Cdx2 
knockout) to investigate whether these lesions underwent 
spontaneous cancerous evolution in aged animals. Pathohisto-
logical examination revealed neither dysplastic nor neoplastic 
structures. At the molecular level, β-catenin remained mem-
branous without any evidence of cytoplasmic/nuclear trans-
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Figure 2. Cecal lesion induced by mosaic gene knockout of Cdx2 in the adult gut epithelium. (A) Histology of cecal lesions in AhCreERT::Cdx2f/f mice 4 
mo after βNF+Tam administration. Bar, 500 µm. The boxed region is magnified in the right panel. Bar, 250 µm. (B) Immunodetection of the Cdx2 protein. The 
protein is almost absent, except in few glands with intact Cdx2 (arrowheads) entrapped in the lesions. Bar, 100 µm. In A and B, n = 20 mice from five crossings. 
(C) Immunodetection of intestinal proteins (Cdx1, Muc2) and gastric proteins (Cldn18, Tff1, Tff2, Sox2) in the cecum of wild-type mice, cecal lesions of Ah-
CreERT::Cdx2f/f mice, cecal heteroplasia of Cdx2+/− mice, and the stomach of wild-type mice. n = 4 animals per genotype from two crossings. Bars, 100 µm. (D) 
Heatmap comparison of transcriptomic data for intestinal and gastric genes in the cecum of wild-type mice (Cec), cecal lesions of AhCreERT::Cdx2f/f mice (CL), 
cecal heteroplasia of Cdx2+/− mice (Het), and the stomach of wild-type mice (Sto). Stomach-1 represents gastric genes up-regulated in CL and Het compared 
with Cec; Stomach-2 represents gastric genes up-regulated in Het but not in CL; Stomach-3 represents gastric genes up-regulated in neither CL nor in Het.
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location (unpublished data). Thus, in >30 AhCreERT::Cdx2f/f 
mice analyzed at various time points, none of the cecal lesions 
spontaneously underwent tumorigenic evolution.
Evolution of the cecal lesions in a tumor-prone context
Based on these observations, the lesions were explored in a can-
cer-prone context by crossing AhCreERT::Cdx2f/f mice with 
Apc+/Δ14 mice (Colnot et al., 2004). Apc+/Δ14 mice develop 
adenomatous polyps predominantly in the small intestine, but 
also a few in the colon and rarely in the cecum (respectively 
18 ± 7 and 1 ± 1 polyps in the small intestine and in the colon 
per mouse, and only 1 polyp every 10 mice in the cecum). 
As previously reported (Colnot et al., 2004), the life span of 
Apc+/Δ14 animals was compromised compared with wild-type 
Figure 3. Functional characterization of the cecal lesions. (A) Gene ontology enrichment analysis for terms related to cancer in the transcriptome 
of the cecal lesions of AhCreERT::Cdx2f/f mice compared with the cecum of wild-type mice. (B) Immunohistochemical staining of Ki67, β-catenin, Sox9, and 
Olfm4 in the cecal lesions; the insets respectively represent the Sox9 and Olfm4 patterns in wild-type cecal glands. Bars: (β-catenin) 100 µm; (Ki67, Sox9, 
and Olfm4) 200 µm. (C) Coimmunofluorescence detection of β-catenin and Cdx2, β-catenin and Sox9, β-catenin and Olfm4, Cdx2 and Sox9, and Cdx2 and 
Olfm4 in serial sections of the stomach, jejunum, and cecum of wild-type mice and in the cecal lesions of AhCreERT::Cdx2f/f mice. In the cecal lesions, open 
squares show a gland depleted in Cdx2, and asterisks show a gland with intact Cdx2. The arrowheads point to the surface epithelium expressing Cdx2. Bars, 
50 µm. Pictures in B and C are representative of the data obtained in n = 4 animals per genotype in two crossings.
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Figure 4. Comparative expression patterns of the Cdx2, Sox9, and Olfm4 proteins in gastrointestinal lesions. (A) Foregut-type heteroplasia in 
the cecum of Cdx2+/− mice. Top: region at the border (dotted line) between the normal cecal mucosa (right side) and the heteroplastic tissue (left side). 
The normal epithelium expresses Cdx2, whereas Sox9 and Olfm4 are present at the bottom of the glands; the heteroplastic tissue, devoid of Cdx2, shows 
a strong expression of Sox9 but no expression of Olfm4. Bottom: rare clusters of glands in the heteroplasia expressing both Sox9 and Olfm4. Bars, 50 µm. 
n = 4 mice. (B) Human lesions: hyperplastic polyp in the stomach (n = 3); gastric-type metaplastic polyp in the duodenum (n = 1); and Meckel diverticulum 
with gastric-type differentiation (n = 3). For the normal small intestinal mucosa (bottom), the crypt-villous axis is from left to right (n = 3). Bars, 50 µm.
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mice and thus also compared with βNF+Tam-injected 
AhCreERT::Cdx2f/f mice; in the cancer-prone context, the 
Apc+/Δ14::AhCreERT::Cdx2f/f mice treated with βNF+Tam 
showed a tendency to an even shorter life span, although this 
was not significantly different from Apc+/Δ14 mice (Fig. 5 A). 
The Apc+/Δ14::AhCreERT::Cdx2f/f mice examined 6–8 mo 
after βNF+Tam administration exhibited polyps in the cecum 
in numbers similar to the cecal lesions of AhCreERT::Cdx2f/f 
mice (one to two polyps per mouse); however, polyps were 
nearly two times more abundant in the small intestine (32 
± 4 vs. 18 ± 7) and five times more abundant in the colon 
(5 ± 2 vs. 1 ± 1) compared with Apc+/Δ14 mice (Fig. 5 B). 
Within the whole population of mice carrying the ApΔ14 al-
lele, we also observed rectal prolapses in higher proportion in 
Apc+/Δ14::AhCreERT::Cdx2f/f mice (31.6%) than in Apc+/Δ14 
mice (21.0%). The higher incidence of rectal prolapses in these 
animals could relate to their tendency for a reduced life span.
Histologically, all the polyps (100%) present in the 
cecum of the Apc+/Δ14::AhCreERT::Cdx2f/f mice showed the 
same typical mixed structure characterized by the juxtapo-
sition of areas resembling the imperfect gastric-type meta-
plastic lesions of AhCreERT::Cdx2f/f mice, with cell nuclei 
regularly arranged at the basal side of the polarized glandular 
epithelium, and areas like the adenomatous polyps of Apc+/Δ14 
mice exhibiting tight dysplastic glands with an altered ar-
chitecture, necrotic figures, cell polarity perturbations, and 
large hyperchromatic nuclei irregularly localized in the cells 
(Fig. 5, C and E). Thus, these polyps are referred to hereafter 
as mixed tumors. As in the cecum, all (100%) of the polyps 
present in the colon of Apc+/Δ14::AhCreERT::Cdx2f/f mice 
corresponded to mixed tumors; in the small intestine, 73% of 
the polyps were mixed tumors, whereas the remaining 27% 
corresponded to typical adenomatous polyps without gas-
tric-type metaplastic structure. Evidence for invasion beyond 
the muscularis mucosae was observed in 15/55 mixed tumors 
of Apc+/Δ14::AhCreERT::Cdx2f/f mice, which indicated adeno-
carcinomatous evolution (Fig.  5 D). Yet this is of the same 
order of magnitude as observed for the polyps of Apc+/Δ14 
mice (12/45). By immunohistochemistry, β-catenin showed 
membranous distribution in the areas resembling the met-
aplastic lesions of AhCreERT::Cdx2f/f mice, but it shifted to 
a diffuse cytoplasmic/nuclear pattern in the areas looking 
like the Apc+/Δ14 adenoma (Fig. 5 D). The dysplastic pictures 
and the altered distribution of β-catenin indicated that cells 
in these areas have undergone tumorigenic evolution. The 
mixed nature of the tumors with the juxtaposition of the 
Figure 5. Mixed tumors developing by mosaic loss of Cdx2 combined with Apc heterozygosity. (A) Survival curve (Kaplan–Meier representation) 
of wild-type (WT), AhCreERT::Cdx2f/f (C), Apc+/Δ14 (A), and Apc+/Δ14::AhCreERT::Cdx2f/f (CA) mice; n = 15 animals of each genotype; p-values were calculated 
using the log-rank test; n.s., not significant. (B) Number of polyps in the small intestine, cecum, and colon of AhCreERT::Cdx2f/f (C), Apc+/Δ14::AhCreERT::Cdx2f/f 
(CA), and Apc+/Δ14 (A) mice; n = 10 mice of each genotype; data are given ± SD; p-values were calculated using the Wilcoxon–Mann–Whitney test; n.s., not 
significant. (C) Histology of a cecal mixed tumor in Apc+/Δ14::AhCreERT::Cdx2f/f mice with the juxtaposition of metaplastic-type (open square) and dysplastic 
areas (asterisk). Bar, 500 µm; n = 15 mice in three crossings. (D) Invasion beyond the muscularis mucosae. Bar, 100 µm. (E) Histology and immunostaining 
of β-catenin and Cdx2 in the metaplastic-type and dysplastic areas. Bars, 50 µm; n = 15 mice in three crossings.
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gastric-type metaplastic area and dysplastic areas was further 
confirmed by transcriptomic analyses. Indeed, Wnt pathway 
components were up-regulated in the cecal mixed tumors of 
Apc+/Δ14::AhCreERT::Cdx2f/f mice compared with the lesions 
of AhCreERT::Cdx2f/f mice (i.e., Axin2, Cldn1, Dsc3, Fosl1, 
Fst, Fzd10, IL6, Lef1, Nkd1, Prox1, Tbx1, Tnfrsf19, and Wnt6), 
whereas gastric-type genes were turned on in the small in-
testinal mixed tumors compared with small intestinal dys-
plastic polyps of Apc+/Δ14 mice (i.e., Atp4a, Car2, Ctse, Gif, 
Gkn1/2/3, Gsdma2, Muc1/6, Pgc, Ptprn2, Tff1/2, and Vsig1; 
Table S2, sheets 1 and 2). Altogether, these results indicate that 
the loss of Cdx2 sensitizes the gut mucosa to tumorigenic 
progression in a cancer-prone context.
Non–cell-autonomous effect of Cdx2 on 
intestinal tumorigenesis
Given that, on the one hand, the knockout of Cdx2 driven by 
AhCreERT is mosaic and that, on the other hand, tumorigene-
sis in Apc+/Δ14 mice results from the sporadic loss of heterozy-
gosity at the Apc locus (Colnot et al., 2004), the juxtaposition 
of metaplastic-type and dysplastic areas within the mixed tu-
mors of Apc+/Δ14::AhCreERT::Cdx2f/f mice may result either 
from the neoplastic conversion of metaplastic Cdx2-depleted 
cells or from detrimental interactions between adjacent cells, 
in that Cdx2-depleted cells would trigger the tumorigenic 
evolution of adjacent Cdx2-intact cells. Here, we addressed 
this issue using a lineage-tracing approach to follow the fate 
of the Cdx2-depleted cells. For this purpose, quadruple trans-
genic mice Apc+/Δ14::AhCreERT::Cdx2f/f::RosaCAGtdTomato 
were produced, in which activation of the Cre recombinase 
by βNF+Tam treatment should simultaneously disrupt the 
Cdx2 gene and turn on fluorescent Tomato protein expres-
sion from the recombined RosaCAGtdTomato allele. Before 
performing this experiment, two series of controls were 
conducted to validate the tracing approach. First, AhCreERT:: 
Cdx2f/f::RosaCAGtdTomato mice were generated and used to 
prove the actual correlation between cells having lost Cdx2 
and cells expressing Tomato after βNF+Tam treatment (Fig. 
S2B). Second, Apc+/Δ14::AhCreERT::RosaCAGtdTomato mice 
were produced, treated with βNF+Tam, and analyzed 5 mo 
later for fluorescence emission; the results illustrated in Fig. S2 
C attest to the preservation of Tomato fluorescence in the ad-
enomatous polyps marked by cytoplasmic/nuclear β-catenin, 
which conversely rules out the possibility that Tomato ex-
pression from the recombined RosaCAGtdTomato allele could 
be secondarily turned off in the dysplastic context. Having 
validated the tracing approach, Apc+/Δ14::AhCreERT::Cdx2f/f:: 
RosaCAGtdTomato mice (n = 4) were analyzed 5 mo after βN-
Figure 6. Tracing of Cdx2-depleted cells in mixed tumors. Detection of β-catenin, Cdx2, and Tomato in small intestinal and cecal mixed tumors of 
Apc+/Δ14::AhCreERT::Cdx2f/f::RosaCAGtdTomato mice. The second line of pictures represents a higher magnification of the first one. Tomato was detected by 
direct fluorescence emission before indirect immunodetection of β-catenin and Cdx2. The mutually exclusive patterns of Tomato and cytoplasmic/nuclear 
β-catenin were obtained in three mixed tumors from the cecum and three mixed tumors from the small intestine coming from four mice in two indepen-
dent crossings, in four sections analyzed in each sample. Bars, 100 µm.
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F+Tam treatment. The results obtained in small intestinal 
and cecal mixed tumors (Fig. 6) led to the following con-
clusions: (a) cells expressing Tomato were devoid of Cdx2 
and always exhibited membranous β-catenin; (b) strong and 
homogenous staining of Cdx2 was restricted to glands ex-
hibiting membranous β-catenin and absence of Tomato; (c) 
Cdx2 was low and heterogeneous in areas with cytoplasmic/
nuclear β-catenin, corresponding to cells having undergone 
tumorigenic evolution; and (d) dysplastic cells with cytoplas-
mic/nuclear β-catenin translocation never expressed Tomato. 
These data indicated that the cells forming the dysplastic area 
in the mixed tumors originated from Cdx2-intact instead of 
Cdx2-knockout cells. Thus, metaplastic-type Cdx2-depleted 
areas do not themselves become tumorigenic, but they cre-
ate a context that stimulates tumorigenesis from adjacent 
Cdx2-intact Apc+/Δ14 tumor-prone cells. This highlights a 
novel property of Cdx2 in the gut, in that this homeobox 
gene exerts a non–cell-autonomous tumor suppressor activity.
The loss of Cdx2 modifies the stromal microenvironment
To investigate how Cdx2 exerts its non–cell-autonomous 
tumor suppressor activity, the transcriptome of the cecal le-
sions of AhCreERT::Cdx2f/f mice was reconsidered to iden-
tify mediators of intercellular communication (Fig. 7 A and 
Table S1, sheets 4 and 5). Several extracellular matrix genes 
potentially involved in tumor growth and progression (Lu et 
al., 2012) were up-regulated, as well as genes for cytokines. 
Among them are Tnf family members, CCL and CXCL 
chemokines, and interleukins. For instance, CCL2 (known 
to shape a tumor-permissive microenvironment; Chun et al., 
2015; Zhang et al., 2015), and IL6 family members (IL6, IL11, 
Osm, and Lif, considered potent drivers of cancer progression; 
Putoczki et al., 2013) were increased, whereas IL15 and IL18 
(with anticancer activity; Salcedo et al., 2010; Bahri et al., 
2015) were decreased. In line with this, the cellular microen-
vironment was also modified, as illustrated by the widespread 
infiltration of macrophages and by the concentration under-
neath the surface epithelium of the lesions of CD4+ T lym-
phocytes and focally of FoxP3+ Treg lymphocytes (Fig. 7 B), 
whereas CD8+ lymphocytes were barely detected.
Cytokines activate signaling pathways through media-
tors such as Erk, STATs, and NF-κB. Phospho-Erk1/2, pres-
ent in crypt base epithelial cells in the normal cecum, shifted 
to an irregular pattern at the surface of the cecal lesions of 
Figure 7. Modification of the microenvironment in the cecal lesions of AhCreERT::Cdx2f/f mice. (A) Heatmap comparison of transcriptomic data 
for extracellular matrix genes (left) and cytokine genes (right) up-regulated in the cecal lesions of AhCreERT::Cdx2f/f mice (CL) compared with the cecum 
of wild-type mice (Cec). (B) Immunodetection of Iba1+ macrophages, CD4+ T lymphocytes, and FoxP3+ Treg lymphocytes in the normal cecal mucosa of 
wild-type mice and cecal lesions of AhCreERT::Cdx2f/f mice. Pictures correspond to serial sections. The asterisks indicate the lumen of the cecum. Bars: (cecum) 
50 µm; (cecal lesions) 100 µm. (C) Erk1/2 and STAT3 signaling in the cecal lesions: the immunostaining illustrates the distribution of phospho-pErk1/2 and 
phospho-STAT3 in the cecal lesions compared with the normal cecum. Closed and open squares respectively show Cdx2-depleted and Cdx2-intact glands. 
Bars: (cecum) 50 µm; (cecal lesions) 100 µm. Pictures in B and C were obtained in four mice of each genotype from two crossings.
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AhCreERT::Cdx2f/f mice and occasionally in subjacent glands, 
regardless of whether they were depleted in Cdx2 (Fig. 7 C). 
Phospho-STAT3 labeled infiltrating cells in the stroma of 
the lesions and sporadically also epithelial cells, irrespective 
of their Cdx2 status (Fig. 7 C). Importantly, the pattern of 
NF-κB was profoundly modified in the lesions (Fig. 8). In-
deed, besides its presence in the nuclei of cells infiltrating 
the stroma, NF-κB was activated and translocated into the 
nucleus of epithelial cells at the surface epithelium composed 
of Cdx2-intact cells; this contrasts with the normal cecal ep-
ithelium, in which nuclear NF-κB is only weakly detected 
with a decreasing gradient from the bottom to the top of the 
crypts. This observation is particularly interesting in light of 
recent findings reporting that gut tumorigenesis can be initi-
ated from non–stem cells instead of stem cells by combining 
the activation of Wnt and NF-κB signaling (Schwitalla et 
al., 2013). Moreover, the activation of the NF-κB pathway 
has been shown to stimulate Apc-dependent tumorigenesis 
in the gut, and this effect was related to the induction of 
iNOS/nos2 by NF-κB (Shaked et al., 2012). Strikingly, tran-
scriptomic data revealed an approximately sixfold increase of 
iNOS/nos2 mRNA in cecal lesions compared with the nor-
mal cecum (q < 0.0001). In addition, this correlated not only 
with the infiltration of the stroma by iNOS-positive cells, 
but also with the focal induction of iNOS in Cdx2-intact 
cells also exhibiting nuclear NF-κB in the surface epithelium 
of the lesions (Fig. 8).
Surface origin and iNOS-dependent 
tumorigenesis in the mixed tumors
These observations prompted us to investigate whether the 
emergence of dysplastic areas within the mixed tumors is ac-
tually associated with Apc loss of heterozygosity, and whether 
the process is initiated at the surface of the lesions and is iNOS 
dependent. PCR genotyping of individual glands microdis-
sected within cecal mixed tumors of Apc+/Δ14::AhCreERT:: 
Cdx2f/f mice showed that the wild-type allele of Apc was pre-
served in the metaplastic-type Cdx2-knockout glands but lost 
in the dysplastic glands, as in typical Apc+/Δ14 adenomatous 
polyps (Fig. 9 A). This indicates a similar molecular mecha-
nism of oncogenic Wnt pathway activation through Apc loss 
of heterozygosity in the dysplastic area of the mixed tumors 
of Apc+/Δ14::AhCreERT::Cdx2f/f mice, as in Apc+/Δ14 mice 
(Colnot et al., 2004).
Next, we addressed the site of emergence of the dys-
plastic area in the mixed tumors. For this purpose, the cy-
toplasmic/nuclear localization of β-catenin was used as a 
marker of the loss of Apc, because Colnot et al. (2004) have 
reported that β-catenin translocation already accompanies 
the loss of Apc in early lesions. First, we entirely cut cecal 
mixed tumors (n = 3) of Apc+/Δ14::AhCreERT::Cdx2f/f mice. 
This led to identification of small invaginations in the surface 
epithelial layer, not connected to deeper glands as assessed 
by serial sections analysis, which contained cells or groups 
of cells with cytoplasmic/nuclear β-catenin; these cells did 
not express Olfm4 (like normal cecum in mice) but exhib-
ited a reduced level of Cdx2 and an increased level of Sox9 
protein compared with adjacent nontransformed cells of 
the epithelial lining in which β-catenin remained membra-
nous (Fig. 9 B and Fig. S3). Second, we analyzed β-catenin– 
immunostained sections coming from nine mixed tumors of 
seven Apc+/Δ14::AhCreERT::Cdx2f/f mice for the position of 
the dysplastic glands in the depth of the polyps. Plotting the 
results obtained for a total of 77 of these structures revealed 
Figure 8. NF-κB activation and iNOS induction in the cecal lesions of AhCreERT::Cdx2f/f mice. Coimmunodetection of Cdx2 and β-catenin, RelA (p65 
NF-κB) and β-catenin, iNOS and β-catenin, RelA and Cdx2, and RelA and Cdx2 in the normal cecal mucosa of wild-type mice and the cecal lesions of Ah-
CreERT::Cdx2f/f mice. Open and closed arrows respectively show Cdx2-devoid and Cdx2-expressing surface epithelium. The asterisk points to a Cdx2-depleted 
gland underneath the surface epithelium. Pictures correspond to serial sections. They were obtained in four mice of each genotype from two independent 
crossings. Bars, 100 µm.
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an uneven distribution: they were all connected to or located 
immediately underneath the surface layer and extended more 
or less deeply into the tumors (Fig. 9 C). Collectively, these 
results suggest that the loss of heterozygosity of Apc occurs 
in the Cdx2-intact surface epithelial layer and that the dys-
plastic structures progressively cover and invade the subjacent 
Cdx2-depleted metaplastic tissue.
Finally, because the dysplastic areas are composed of 
Cdx2-intact cells and emerge from the surface of the lesion, 
and because the surface cells focally express iNOS, which 
is known to accelerate Apc loss and initiate tumorigenesis 
(Shaked et al., 2012), we investigated the involvement of iNOS 
in the emergence of dysplasia in Apc+/Δ14::AhCreERT::Cdx2f/f 
mice. For this purpose, animals were treated with βNF+Tam 
and, 2 wk later, given the iNOS inhibitor aminoguanidine 
(AG) ad libitum in drinking water for 3 mo. Sections of the 
lesions developing in the cecum of these mice were analyzed 
histologically and by immunostaining for Cdx2 and β-catenin 
to identify and record the metaplastic-type area and dysplastic 
areas. As illustrated in Fig. 9 D, three of the four cecal lesions 
analyzed in AG-treated mice showed no dysplastic area, and 
the fourth lesion exhibited only a small area of this type of 
structure; this contrasted with the higher proportion of dys-
plastic areas observed in every cecal mixed tumor of untreated 
mice. In parallel, we observed that the AG treatment reduced 
the tumor load in the small intestine (10 ± 3 vs. 28 ± 4) and 
colon (2 ± 1 vs. 5 ± 2) of these Apc+/Δ14::AhCreERT::Cdx2f/f 
mice compared with untreated mice, whereas it had no sig-
nificant effect in Apc+/Δ14 mice (13 ± 6 vs. 14 ± 3 tumors in 
the small intestine and 1 ± 1 vs. 0 in the colon). These results 
suggest that iNOS actually contributes to the emergence of 
dysplasia in the context of the Apc+/Δ14::AhCreERT::Cdx2f/f 
mice; moreover, they are consistent with the data reported 
by Shaked et al. (2012) showing that the iNOS inhibitor AG 
Figure 9. Surface initiation and iNOS-dependence of the dysplastic structures in mixed tumors. (A) Genotyping of microdissected glands for 
the Apcwt and ApcΔ14 alleles: (1) normal cecal gland and (2) Cdx2-depleted gland in cecal lesions of AhCreERT::Cdx2f/f mice; (3) normal and (4) dysplastic 
gland in Apc+/Δ14 mice; (5) normal cecal gland, (6) metaplastic-type gland, and (7) dysplastic gland in mixed tumors of Apc+/Δ14::AhCreERT::Cdx2f/f mice. PCR 
results are representative of the results obtained in n = 3 mice. (B) Immunodetection of β-catenin, Cdx2, Olfm4, and Sox9 in the Cdx2-expressing surface 
epithelium of mixed tumors. The arrowheads point to surface epithelial cells with cytoplasmic/nuclear β-catenin; the asterisks show Cdx2-depleted glands. 
Pictures correspond to serial sections. They were obtained in n = 10 mice. Bars, 50 µm. (C) Left: localization of the dysplastic glands in mixed tumors by 
β-catenin immunostaining, showing cytoplasmic/nuclear accumulation in glands connected to the surface epithelium. Bar, 100 µm. Right: distribution of 
dysplastic glands. Each bar represents the localization and extent of one dysplastic structure along the surface-to-bottom axis of mixed tumors. Results are 
expressed as percentage of the height of the mixed tumors. They correspond to data obtained from nine mixed tumors in seven mice. (D) Surface (square 
millimeters) of the metaplastic-type areas (light gray) and dysplastic areas (dark gray) in the lesions developed in the cecum of Apc+/Δ14::AhCreERT::Cdx2f/f 
mice either untreated or treated with AG. Values represent the mean surfaces in 12 sections for each sample. They were obtained from n = 4 AG-treated 
mice and n = 4 untreated mice.
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does not significantly hamper Apc-dependent tumorigenesis 
unless it is triggered by NF-κB/iNOS activation.
DISCUSSION
Based on clinical data showing that the strong reduction of the 
homeobox gene CDX2 in human CRC correlates with poor 
evolution of the disease, we used a mouse model of mosaic 
knockout to address the long-term effect of this gene’s defi-
ciency in the gut. Although abrogating the function of Cdx2 
results in the formation of imperfect gastric-type metaplastic 
lesions, these lesions did not spontaneously evolve in can-
cer even in aged animals. This is consistent with the fact that 
overexpressing a dominant-negative splicing variant of Cdx2 
in the duodenum also led to the formation of lesions with 
gastric-type metaplastic properties without spontaneous neo-
plastic evolution (Balbinot et al., 2017). Nevertheless, by devel-
oping the original model that combines the mosaic knockout 
of Cdx2 with the stochastic loss of function of the Apc tumor 
suppressor gene, we uncovered that functional interactions 
between distinct types of noncancerous epithelial cells—met-
aplastic-type and tumor-prone, respectively—can accelerate 
tumorigenesis. These deleterious interactions are indirect and 
involve modifications of the microenvironment driven by the 
metaplastic-type Cdx2-deficient cells that trigger chronic ac-
tivation of NF-κB and induction of iNOS in Cdx2-intact 
tumor-prone cells, which subsequently undergo Apc loss of 
heterozygosity and generate dysplastic structures. Thus, this 
study highlights a novel and original property of Cdx2 in the 
gut, in that this homeobox gene exerts non–cell-autonomous 
tumor suppressor activity mediated by changes in the stromal 
environment. Because the cecal epithelium can be the seat of 
adenomatous development in Apc+/Δ14 mice, even at a very 
low rate, we believe that the environment created by the met-
aplastic-type Cdx2-depleted cells would stimulate Apc loss of 
function in the adjacent Cdx2-intact cells rather than bring-
ing out latent mutations. The non–cell-autonomous tumor 
suppressor activity represents a new property for this homeo-
box gene, already reported to exhibit cell-autonomous tumor 
suppressor activity in the gut through its impact on many cel-
lular and molecular functions including apoptosis, cell differ-
entiation, cell proliferation, chromosome stability, and DNA 
repair (Aoki et al., 2003; Bonhomme et al., 2003; Renouf et 
al., 2012; Sakamoto et al., 2017; Tong et al., 2017). Only a few 
examples of non–cell-autonomous tumor suppressor activ-
ity have been described so far, for instance in liver and brain 
tumors and also in melanoma (Andoniadou et al., 2013; Lu-
jambio et al., 2013; Mescher et al., 2017), probably because it 
needs to develop appropriate lineage tracing approaches. This 
mechanism is likely underrated despite its potential not only 
for tumor initiation, but also in the emergence of subclonal 
heterogeneity (Marusyk et al., 2014).
The findings reported here are important regarding the 
pathological relevance of metaplastic-type lesions displayed in 
a wide range of epithelial organs, including, for instance, the 
digestive, respiratory, and urinary tracts. Indeed, metaplasia is 
generally considered precancerous because of its presumptive 
sensitivity to progress into neoplasia. Here, we provide a novel 
paradigm in that metaplastic cells can also trigger tumorigen-
esis without themselves becoming cancerous but by inducing 
the cancerous evolution of adjacent nonmetaplastic cells. The 
reason why Cdx2-depleted metaplastic-type cells do not be-
come dysplastic, unlike adjacent Cdx2-intact cells, is unknown. 
One possibility is related to the fact that that these cells show 
a strong induction of Sox9 and Olfm4, which have been re-
ported to antagonize tumorigenesis (Bastide et al., 2007; Liu 
et al., 2016; Prévostel et al., 2016). Also remarkable is that the 
tumorigenic evolution of Cdx2-intact cells does not occur in 
glands randomly embedded in the metaplastic lesions, but at 
the level of Cdx2-intact cells of the surface epithelial layer. This 
surface is made of patches of Cdx2-intact cells, Cdx2-depleted 
cells, and also eroded areas. Previous studies have shown that 
reducing the Cdx2 level in mice increases intestinal permeabil-
ity and sensitivity to proinflammatory treatment (Calon et al., 
2007), and that Cdx2 modulates the motility and mechanical 
properties of the intestinal epithelial cells (Gross et al., 2008; 
Platet et al., 2017). Therefore, the mosaic deletion of Cdx2 cre-
ates a complex picture with abrasion and tissue repair from 
Cdx2-intact and Cdx2-deleted cells, which may contribute 
to the resulting modification of the underpinning stroma. The 
surface epithelial lining of the lesions is therefore at a critical 
position at the interface between the luminal content with the 
microbiota and the activated stroma, which may facilitate Apc 
loss of heterozygosity. The surface origin of the dysplasia rep-
resents an alternative to the model of tumor initiation in the 
crypt stem cells (Barker et al., 2009). It is in line with previ-
ous descriptions of top-down morphogenesis of colon cancers 
in humans (Shih et al., 2001) and with the mouse model of 
tumorigenesis initiated from dedifferentiated cells located in 
small intestinal villi by combining the activation of the Wnt 
and NF-κB pathways (Schwitalla et al., 2013).
Corroborating previous studies, our data strengthen the 
notion that human CRCs with a strong reduction of CDX2 
principally segregate within the subtype of serrated neoplasia 
with a stem cell signature (De Sousa E Melo et al., 2013; Bae 
et al., 2015; Dalerba et al., 2016) and also are characterized 
by the ectopic expression of gastric markers (Matsuda et al., 
2010; Sentani et al., 2013; Kim et al., 2015). These cancers 
exhibit a worse evolution. Importantly, the lesions developing 
here after Cdx2 loss in mice share several stromal and im-
mune properties with the serrated subtype of human CRCs 
(Becht et al., 2016). These include a high expression of ex-
tracellular matrix molecules, myeloid chemokine Ccl2, com-
plement components (C1qb, C1qc, C1ra, C1rb, C1s, C3, Cfh, 
and Cfi), angiogenic factors (Vegfb, Pdgfb, Pdgfc, and Pdgfd), 
and immunosuppressive molecules (Tgfb2, Tgfb3, Lgals1, 
and Lgals2). These similarities make the mice developed in 
this study a relevant animal model to investigate the com-
plex modifications of the microenvironment leading to the 
neoplastic conversion of premalignant lesions. This is central 
in the perspective of the development of efficient preventive 
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strategies and treatments of cancer targeting the microenvi-
ronment and its interaction with tumor cells.
MATERIALS AND METHODS
Human CRC samples and analysis
The 566 transcriptomic profiles recorded in GSE39582l 
(Marisa et al., 2013) were analyzed. Comparison of the ex-
pression levels of CDX2 between the C4 CRC subtype and 
the other subtypes was performed using independent two-
group t test (function t.test, stats R package). CRC subtypes 
means comparison was performed using Tukey post hoc test 
after two-way ANO VA (function TukeyHSD, stats R pack-
age). Disease-free survival was defined as the time from sur-
gery to the first recurrence. Survival curves were obtained 
according to the method of Kaplan and Meier (function Surv, 
R package survival), and differences between survival distri-
butions were assessed by log-rank test.
Human tissue samples were obtained at the University 
Hospital of Strasbourg (France) according to the recommen-
dations of the French Ethical Committee and the ethical 
standards of the 1964 Declaration of Helsinki. Patients pro-
vided written informed consent.
Mouse strains and treatments
Mice were used according to the protocol approved by the 
Committee on the Ethics of Animal Experiments of the 
University of Strasbourg (CRE MEAS, C2EA-35) under the 
permit number AL/43/50/02/13. AhCreERT (Ireland et al., 
2004), AhCreERT::Cdx2f/f (Stringer et al., 2012), and Apc+/Δ14 
mice (Colnot et al., 2004) have been described. Rosa-
CAGtdTomato mice (strain Ai9) were provided by the Jackson 
Laboratory. Strains were backcrossed at least eight times. Lit-
termates were used as controls throughout this study.
Mice were genotyped by PCR amplification of tail 
DNA (Viagene, DirectPCR Lysis Reagent mouse tail; Eu-
romedex) using the following primers: Cdx2wt and Cdx2f 
alleles, 5′-TGG GGC AAT CTT AAT GGG TA-3′ and 5′-TGT 
AGC CTC GAC TTG GCT TT-3′; Apcwt allele, 5′-CTG TTC 
TGC AGT ATG TTA TCA-3′ and 5′-CTA TGA GTC AAC 
ACA GGA TTA-3′; ApcΔ14 allele, 5′-CTG TTC TGC AGT 
ATG TTA TCA-3′ and 5′-TAT AAG GGC TAA CAG TCA 
ATA-3′; AhCreERT allele, 5′-GCC TGG TCT GGA CAC 
AGT CC-3′ and 5′-GGT TCA GCA TCC AAC AAG GC-
3′; RosaCAGtdTomato allele, 5′-CTG TTC CTG TAC GGC 
ATGG-3′ and 5′-GGC ATT AAA GCA GCG TAT CC-3′; and 
Rosawt allele, 5′-AAG GGA GCT GCA GTG GAG TA-3′ and 
5′-CCG AAA ATC TGT GGG AAG TC-3′.
Mice 3 mo of age were intraperitoneally injected with 
1.6 mg βNF+TAM (Sigma-Aldrich) in corn oil, once daily 
for 4 d. For the treatment with the iNOS inhibitor, they 
were injected with βNF+Tam, and 2 wk later they were 
given 2  g/L AG (Sigma-Aldrich) in drinking water. The 
pathohistological evaluation of the lesions developed in the 
mice used in this study was performed independently by 
two pathologists of the University Hospital of Strasbourg: 
A. Onea and M.P. Chenard.
RNA extraction and analysis by RNA sequencing
RNA was extracted from tissue fragments with Tri Reagent 
(Euromedex) and analyzed using nanoRNA chips on a Bio-
analyser 2100 (Agilent Technologies). 1 µg of total RNA was 
used for the construction of the mRNA sequence libraries 
with Illumina’s TruSeq RNA sample kit (Illumina). Poly(A) 
RNA was selected by two rounds on poly-dT–coated 
magnetic beads, followed by fragmentation and first-strand 
cDNA synthesis with Superscript II (Thermo Fisher Scien-
tific) using random hexamer primers. The cDNA fragments 
were subjected to end repair and dA tailing, ligated to in-
dexed bar-coded adapters, and subjected to 12 cycles of PCR. 
Concentration and validation of the libraries were made with 
DNA1000 chips loaded on a Bioanalyser 2100. Paired-end 
50-bp reads were obtained with a HiSeq1000 by multiplex-
ing three libraries on one lane. Demultiplexing and gener-
ation of raw fastq files were performed with Casava v1.7. 
Mapping against the reference mouse genome GRCm38 
was performed with tophat 2 (Trapnell et al., 2009) using 
the following options: b2-sensitive, a 5, p 5, library-type, 
fr-unstranded, r 180, mate-std-dev 80, and exon-exon ref-
erence from Ensembl v75. Quantification of the reads was 
performed with HTSeq v.0.5.3p3 (Anders et al., 2015) with 
the following options: stranded = no, mode = union; and 
using the reference gene annotation from Ensembl v75. 
Normalization and differential expression analysis was made 
with DESeq2 (Love et al., 2014). Unless otherwise stated, 
genes with a log2(fold change [FC]) ≥1 and adjusted p-value 
(q-value) <0.01 were considered as differentially expressed. 
Data analysis was performed using Ingenuity Pathway Anal-
ysis (Qiagen). The transcriptomic data have been deposited 
in the GEO database under accession number GSE89992.
Histology and immunohistology
Tissue samples were fixed with 4% PFA and embedded in 
paraffin. Sections (5 µm) were deparaffinized and treated for 
antigen retrieval for 10 min in 10 mmol/L sodium citrate, pH 
6, in a microwave oven for every primary antibody except an-
ti-Iba1, and then blocked in 5% normal goat serum and 0.1% 
Triton X-100–PBS for 1 h at room temperature. Slides were 
incubated overnight at 4°C with primary antibodies diluted 
in 0.1% Triton X-100–PBS and washed in this saline buffer. 
Primary antibodies were as follows: mouse anti–β-catenin 
(clone 14; dilution 1:500; BD Transduction Lab), mouse an-
ti-CD4 (50134-M08H; dilution 1:500; Sino Biological), goat 
anti-CD8b (M-20, sc-1144; dilution 1:500, Santa Cruz Bio-
technology), rabbit anti-Cdx1 (Bonhomme et al., 2003; dilu-
tion 1:1,000), mouse anti-Cdx2 (CDX2-88, F/MU392A-UC; 
dilution 1:500; Biogenex), rabbit anti-Cdx2 (EPR2764Y, 
ab76541; dilution 1:10,000; Thermo Fisher Scientific), rabbit 
anti-Cldn18 (38-8000; dilution 1:500; Invitrogen), rat anti- 
FoxP3 (FJK-16s, 14-5773-80; dilution 1:500; Affymetrix eBio-
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science), rabbit anti-Iba1 (orb10863; dilution 1:500; Bior-
byt), rabbit anti-iNOS (M-19, sc-650; dilution 1:500; Santa 
Cruz Biotechnology), rabbit anti-Ki67 (RM9106-S; dilution 
1:500; Thermo Fisher Scientific), rabbit anti-Muc2 (H-300, 
sc-15334; dilution 1:1,000; Santa Cruz Biotechnology), rab-
bit anti-Olfm4 (D6Y5A, mouse-specific; dilution 1:500; Cell 
Signaling Technology), rabbit anti-Olfm4 (ab85046, human- 
specific; dilution 1:500; Abcam), rabbit anti-p-Erk1/2 (D11A8, 
mAb5683; dilution 1:500; Cell Signaling Technology), rabbit 
anti–p-STAT3 (ab76315; dilution 1:500; Abcam), rabbit anti- 
RelA (NF-κB p65; C-20, sc-372; dilution 1:500; Santa Cruz 
Biotechnology), rabbit anti-Sox2 (AB5603; dilution 1:500; 
Millipore), rabbit anti-Sox9 (De Santa Barbara et al., 1998; 
dilution 1:500), rabbit anti-Tff1 (Karam et al., 2004; dilution 
1:500), rabbit anti-Tff2 (Karam et al., 2004; dilution 1:500), and 
rat anti-Tomato (clone 16D7; dilution 1:250; KerFast). For im-
munohistochemical staining, secondary biotinylated antibodies 
(dilution 1:2,000; Vector Laboratories) were revealed using the 
Vectastain ABC kit (Vector Laboratories). For immunofluores-
cence detection, secondary goat anti-mouse antibody labeled 
with Alexa Fluor 488 (dilution 1:1,000; Molecular Probes) 
and goat anti-rabbit antibody labeled with Alexa Fluor 568 
(dilution 1:1,000; Molecular Probes) were used. Sections were 
visualized with an Axio Zoom.V16 microscope, an Axiophot 
microscope, or an Axio Imager Z2 microscope (Zeiss).
For the combined detection of Tomato, β-catenin, and 
Cdx2 proteins in tissue sections, a two-step procedure was de-
veloped. In the first step, sections were deparaffinized and cov-
ered with 0.1% Triton X100–PBS buffer, and a picture of the 
direct fluorescence emitted by Tomato was taken. In the sec-
ond step, the sections were treated for antigen retrieval for 10 
min in 10 mmol/L sodium citrate, pH 6, in a microwave oven, 
which (a) destroys the direct fluorescence emission by Tomato 
and (b) allows further detection of β-catenin and Cdx2 by in-
direct immunofluorescence labeling, as described in the above 
paragraph. To validate this procedure, we verified that the de-
tection of Tomato by direct fluorescence emission in deparaf-
finized sections was as efficient as the detection of the Tomato 
protein by indirect immunofluorescence in the same sections. 
For this purpose, cecal sections of AhCreERT::RosaCAGtdTomato 
mice treated with βNF+Tam were first processed for Tomato 
detection by direct fluorescence emission, and then the To-
mato protein was revealed by indirect immunofluorescence 
using the anti-Tomato antibody. The results illustrated in Fig. 
S2 A demonstrate perfect superimposable patterns.
Tissue microdissection for genomic PCR analysis
Tissue sections of 10 µm fixed in 4% PFA and embedded in 
paraffin were sliced on FrameSlides PET Membrane slides 
(Leica) and stained with Harris, and serial sections were im-
munostained for β-catenin and Cdx2 to ascertain the identity 
of the microdissected glands. Areas of ∼100 cells were micro-
dissected using an LMD 6000 laser microscope (Leica Mi-
crosystems), and genomic DNA was extracted using QIAamp 
DNA FFPE Tissue kit (Qiagen). Identification of the Apcwt 
and ApcΔ14 alleles was performed by PCR using the same 
primers as for animal genotyping.
Online supplemental material
Fig. S1 shows the results of the analysis of the transcriptomic 
data of the human CRC collection using the consensus clas-
sification system (Guinney et al., 2015). Fig. S2 illustrates 
control experiments performed for the lineage tracing ap-
proach. Fig. S3 shows the immunofluorescence patterns of 
β-catenin and Cdx2 in serial sections of mixed tumors. Table 
S1 provides the list of genes differentially expressed between 
the cecal lesions of AhCreERT::Cdx2f/f mice and the normal 
cecum (sheet 1) and lists of selected panels of genes selected 
from this list (intestinal/gastric markers, stem cell markers, 
extracellular matrix components, and cytokines, respec-
tively; sheets 2–5). Table S2 provides the list of genes differ-
entially expressed between cecal mixed tumors of Apc+/Δ14:: 
AhCreERT::Cdx2f/f mice and cecal metaplastic-type lesions of 
AhCreERT::Cdx2f/f mice (sheet 1) and between small intesti-
nal mixed tumors of Apc+/Δ14::AhCreERT::Cdx2f/f mice and 
small intestinal adenoma of Apc+/Δ14 mice (sheet 2).
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